Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.49 |
| ▸ | CA2 | P00918 | 11/20 | 0.49 |
| ▸ | CA9 | Q16790 | 11/20 | 0.49 |
| ▸ | CA12 | O43570 | 4/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.49 |
| ▸ | CA4 | P22748 | 7/20 | 0.49 |
| ▸ | CA7 | P43166 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16479569 | 0.84 | CA1 (0.54) | CA1CA2CA9CA12ADRB2 | |
| SCHEMBL19683419 | 0.84 | CA1 (0.54) | CA1CA2CA9CA12ADRB2 | |
| SCHEMBL29813063 | 0.83 | LMNA (0.56) | CA1CA2CA9CA12ADRB2 | |
| SCHEMBL5041575 | 0.83 | LMNA (0.48) | CA1CA2CA9CA12ADRB2 | |
| SCHEMBL16093348 | 0.83 | CA1 (0.54) | CA1CA2CA9CA12ADRB2 | |
| SCHEMBL19683202 | 0.83 | CA1 (0.54) | CA1CA2CA9CA12ADRB2 | |
| SCHEMBL21156445 | 0.83 | LMNA (0.40) | CA1CA2CA9CA12ADRB2 | |
| SCHEMBL11579471 | 0.81 | PTGS1 (0.67) | CA1CA2CA9CA12ADRB2 | |
| SCHEMBL9969518 | 0.80 | CA1 (0.50) | CA1CA2CA9CA12ADRB2 | |
| SCHEMBL13526942 | 0.80 | CA1 (0.50) | CA1CA2CA9CA12ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | CA1 3502/4885CA2 3747/4885CA9 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.